Zhixing Finance APP learned that Kelunbotai Bio-B (06990) rose nearly 4%, as of the press release, up 3.98% to HKD 169.70, with a turnover of HKD 8.0459 million.
CMB International released a research report stating that at the American Society of Clinical Oncology (ASCO) annual meeting, Kelunbotai Bio-B's core product SKB264 is expected to achieve good efficiency in its opinion, and the product is expected to be widely used in non-small cell lung cancer (NSCLC), and the strong results of SKB264's Phase III clinical trial for triple-negative breast cancer will help it obtain approval in the mainland.